# US 2025/0144144 A1 · BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144144 A1
- Document ID: US20250144144A1
- Status: Published application
- Kind: A1
- Application number: 19/015,063
- Filed: 2025-01-09
- Published: 2025-05-08
- Earliest claimed: 2014-12-15
- Assignees: The Regents of the University of California; Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Applicants: The Regents of the University of California; Seattle Children's Hospital DBA Seattle Children's Research Institute
- Inventors: Yvonne Y. Chen; Eugenia Zah; Michael C. Jensen
- Web page: https://patentgrep.com/patent/US20250144144A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4221: {CD20}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2887: {against CD20}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C12N 5/0636: {T lymphocytes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/29: Multispecific CARs
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of assessing at least one property in a population of T cells expressing a polypeptide comprising a CD19-OR-CD20 chimeric antigen receptor (CAR), the CAR comprising, in order: anti-CD20 scFv comprising a light chain variable region and heavy chain variable region from SEQ ID NO:3; (G4S)4 linker; anti-CD19 scFv comprising a heavy chain variable region and light chain variable region from SEQ ID NO:4; spacer domain of SEQ ID NO:5; transmembrane domain of SEQ ID NO:6; 4-1BB cytoplasmic signaling domain of SEQ ID NO:8; and CD3 zeta cytoplasmic signaling domain of SEQ ID NO:9; and
wherein the at least one property is selected from the group consisting of surface expression of at least one activation-induced marker on the T cells, cell lysis of target cells, release of at least one cytokine in the presence of target cells, bispecificity of the CAR, and abrogation of the effects of antigen escape.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one property is assessed by flow cytometry or a cytometric bead array assay.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cell lysis of the target cells is assessed by co-culturing the T cells with wildtype (CD19+/CD20+) or CD19− Raji (CD19−/CD20+) cells.

### Claim 20 (depends on 17)

The method of claim 17, wherein the cell lysis of the target cells is at least about 40%.

### Claim 21 (depends on 17)

The method of claim 17, wherein the surface expression of the at least one activation-induced marker comprises expression of CD69, CD137, and/or CD107a.

### Claim 22 (depends on 21)

The method of claim 21, wherein the expression of CD69, CD137, and/or CD 107a is at least about a 0.5-fold increase relative to T cells expressing a polypeptide comprising a single input CAR.

### Claim 23 (depends on 17)

The method of claim 17, wherein the at least one cytokine comprises IFN-γ, IL-2, and/or TNF-α.

### Claim 24

A method of assessing at least one property in a population of T cells expressing a polypeptide comprising a CD19-OR-CD20 chimeric antigen receptor (CAR), wherein the CAR comprises from N- to C-terminus:
a) an anti-CD20 scFv consisting of a variable light domain and a variable heavy domain from ofatumumab;
b) a (G4S)n linker, wherein n is 1 (SEQ ID NO: 15), 3 (SEQ ID NO: 16), or 4 (SEQ ID NO: 19);
c) an anti-CD19 scFv comprising a variable heavy domain and a variable light domain from a sequence of SEQ ID NO: 4;
d) a spacer of SEQ ID NO: 5;
e) a transmembrane domain of SEQ ID NO: 6;
f) a co-stimulatory domain of SEQ ID NO: 8; and
g) a CD3-zeta cytoplasmic signaling domain of SEQ ID NO: 9,
wherein the at least one property is selected from the group consisting of surface expression of at least one activation-induced marker on the T cells, cell lysis of target cells, release of at least one cytokine in the presence of target cells, bispecificity of the CAR, and abrogation of the effects of antigen escape.

### Claim 25 (depends on 24)

The method of claim 24, wherein the at least one property is assessed by flow cytometry or a cytometric bead array assay.

### Claim 26 (depends on 24)

The method of claim 24, wherein the cell lysis of the target cells is assessed by co-culturing the T cells with wildtype (CD19+/CD20+) or CD19− Raji (CD19−/CD20+) cells.

### Claim 27 (depends on 24)

The method of claim 24, wherein the cell lysis of the target cells is at least about 40%.

### Claim 28 (depends on 24)

The method of claim 24, wherein the surface expression of the at least one activation-induced marker comprises expression of CD69, CD137, and/or CD107a.

### Claim 29 (depends on 28)

The method of claim 28, wherein the expression of CD69, CD137, and/or CD 107a is at least about a 0.5-fold increase relative to T cells expressing a polypeptide comprising a single input CAR.

### Claim 30 (depends on 24)

The method of claim 24, wherein the at least one cytokine comprises IFN-γ, IL-2, and/or TNF-α.

### Claim 31

A method of assessing at least one property in a population of T cells expressing a polypeptide comprising a CD19-OR-CD20 chimeric antigen receptor (CAR), wherein the CAR comprises from N-to C-terminus:
a) an anti-CD20 scFv comprising a variable heavy domain and a variable light domain from a sequence of SEQ ID NO: 3;
b) a flexible peptide linker consisting of Gly and Ser residues;
c) an anti-CD19 scFv comprising a variable light domain and a variable heavy domain from a sequence of SEQ ID NO: 4;
d) a spacer domain;
e) a transmembrane domain;
f) a co-stimulatory domain of SEQ ID NO: 8; and
g) a CD3-zeta cytoplasmic signaling domain of SEQ ID NO: 9,
wherein the at least one property is selected from the group consisting of surface expression of at least one activation-induced marker on the T cells, cell lysis of target cells, release of at least one cytokine in the presence of target cells, bispecificity of the CAR, and abrogation of the effects of antigen escape.

### Claim 32 (depends on 31)

The method of claim 31, wherein the at least one property is assessed by flow cytometry or a cytometric bead array assay.

### Claim 33 (depends on 31)

The method of claim 31, wherein the cell lysis of the target cells is assessed by co-culturing the T cells with wildtype (CD19+/CD20+) or CD19− Raji (CD19−/CD20+) cells.

### Claim 34 (depends on 31)

The method of claim 31, wherein the cell lysis of the target cells is at least about 40%.

### Claim 35 (depends on 31)

The method of claim 31, wherein the surface expression of the at least one activation-induced marker comprises expression of CD69, CD137, and/or CD107a.

### Claim 36 (depends on 35)

The method of claim 35, wherein the expression of CD69, CD137, and/or CD 107a is at least about a 0.5-fold increase relative to T cells expressing a polypeptide comprising a single input CAR.

### Claim 37 (depends on 31)

The method of claim 31, wherein the at least one cytokine comprises IFN-γ, IL-2, and/or TNF-α.
